If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
== Introduction == Unlike epithelial cells – which are stationary and characterized by an apico-basal polarity with binding by a basal lamina, tight junctions, gap junctions, adherent junctions and expression of cell-cell adhesion markers such as E-cadherin, mesenchymal cells do not make mature cell-cell contacts, can invade through the extracellular matrix, and express markers such as vimentin, fibronectin, N-cadherin, Twist, and Snail. MET plays also a critical role in metabolic switching and epigenetic modifications. In general, epithelium-associated genes are upregulated and mesenchyme-associated genes are downregulated in the process of MET.
The positive side of freedom of association is that the law protects everyone against adverse action for joining a union, and also taking part in collective action including strikes that count as "protected industrial action". If an employee alleges that the employer has taken adverse action for a prohibited reason, "it is presumed that the action was, or is being, taken for that reason or with that intent, unless the [employer] proves otherwise." The claimant may apply to the Fair Work Commission which holds a conference, compulsory in cases of dismissal, and the FWC may arbitrate with the parties' consent. Despite the intent of Parliament, in Board of Bendigo Regional Institute of Technical and Further Education v Barclay the High Court held that the reverse burden of proof made it legitimate to focus on the subjective reasons of the decision-maker, so that direct "testimony from the decision-maker which is accepted as reliable is capable of discharging the burden", and that this achieved a "balance". The High Court repeated this stance in CFMEU v BHP Coal Pty Ltd, where a striking worker held a sign saying "No principles SCABS No Guts", and was dismissed for violating BHP's "workplace conduct policy". The High Court sided with the employer's assertion that dismissal was for uncivil language, not union activity, and said that a claimant would only be protected from an employer's deliberate and conscious victimisation, not employers who make out they (supposedly) inadvertently took adverse action.
ISBN 978-0-87220-923-7. Powell, Anton (1990). Euripides, Women and Sexuality. Routledge Press. ISBN 0-415-01025-X. Pucci, Pietro. "Survival in the Holy Garden." The Violence of Pity In Euripides’ “Medea,” vol. 41, Cornell University Press, 1980, pp. 91–130. JSTOR, http://www.jstor.org/stable/10.7591/j.cttq44w0.6. Accessed 27 Mar. 2023. Rabinowitz, Nancy S. (1993). Anxiety Veiled: Euripides and the Traffic in Women. Cornell University Press. ISBN 0-8014-8091-4. Saïd, Suzanne (2002). "Greeks and Barbarians in Euripides' Tragedies: The End of Differences?". In Harrison, Thomas (ed.). Greeks and Barbarians. Translated by Antonia Nevill. Taylor & Francis. ISBN 0-415-93959-3. Sommerstein, Alan (2002). Greek Drama and Dramatists. Routledge Press. ISBN 0-203-42498-0. ISBN 978-0-203-42498-8 Tessitore, Aristide. "Euripides’ ‘Medea’ and the Problem of Spiritedness." The Review of Politics, vol. 53, no. 4, 1991, pp. 587–601. JSTOR, JSTOR 1407307. Accessed 27 Apr. 2023. Tigani, Francesco (2010), Rappresentare Medea. Dal mito al nichilismo, Aracne. ISBN 978-88-548-3256-5 Mossman, Judith (2011). Medea: Introduction, Translation and Commentary. Warminster: Aris & Phillips. ISBN 978-0-856-68788-4.
=== Humanitarian response === The Lebanon Humanitarian Fund launched its reserve allocation that includes up to US$4 million to support its partners to help aid those who have been displaced or still in conflict zones.
Chondrocytes (, from Greek χόνδρος (chondros) 'cartilage' and κύτος (kytos) 'cell') are the only cells found in healthy cartilage. They produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans. Although the word chondroblast is commonly used to describe an immature chondrocyte, the term is imprecise, since the progenitor of chondrocytes (which are mesenchymal stem cells) can differentiate into various cell types, including osteoblasts. From least- to terminally-differentiated, the chondrocytic lineage is:
Sources: en.wikipedia.org
Counter-Strike has over 20 years of competitive play beginning with the original Counter-Strike. The first major tournament was hosted in 2001 at the Cyberathlete Professional League which, along with World Cyber Games and Electronic Sports World Cup, were among the largest tournaments for the Counter-Strike series up to 2007. Since 2013, the Valve-sponsored Counter-Strike: Global Offensive Major Championships have become the most prestigious tournaments in the franchise's history, featuring prize pools of around $1,000,000.
=== Legal status === Empagliflozin/metformin was approved for use in the European Union in May 2015. Empagliflozin/metformin was approved for use in the United States in August 2015. The extended release version was approved for use in the United States in December 2016. Empagliflozin/metformin was approved for use in Australia in May 2020.
== Adverse effects == In the United States, manufacturers of dietary supplements are required to demonstrate safety of their products before approval is granted for commerce. Despite this caution, numerous adverse effects have been reported, including muscle cramps, hair loss, joint pain, liver disease, and allergic reactions, with 29% of the adverse effects resulting in hospitalization, and 20% in serious injuries or illnesses. The potential for adverse effects also occurs when individuals consume more than the necessary daily amount of vitamins or minerals that are needed to maintain normal body processes and functions. The incidence of adverse effects reported to the FDA were due to "combination products" that contain multiple ingredients, whereas dietary supplements containing a single vitamin, mineral, lipid product, and herbal product were less likely to cause adverse effects related to excess supplementation. Among general reasons for the possible harmful effects of dietary supplements are: a) absorption in a short time, b) manufacturing quality and contamination, and c) enhancing both positive and negative effects at the same time. The incidence of liver injury from herbal and dietary supplements is about 16–20% of all supplement products causing injury, with the occurrence growing globally over the early 21st century.
=== Addiction and tolerance === Though there is no evidence that ketamine can cause physical dependence, some people who regularly use it can develop an addiction to it. Animal experiments also confirm the risk of misuse. Additionally, the rapid onset of effects following insufflation may increase potential use as a recreational drug. The short duration of effects promotes bingeing. Ketamine tolerance rapidly develops, even with repeated medical use, prompting the use of higher doses. Some users have reported withdrawal symptoms, primarily anxiety, tremor, sweating, and palpitations, following the attempts to stop; however, these effects have never been objectively measured in the way that physical withdrawal symptoms from drugs like opioids or benzodiazepines have.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.